• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

源自卵巢的假性黏液瘤腹膜转移的突变特征和预后指标。

The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.

机构信息

Department of Myxoma, Aerospace Center Hospital, Beijing, China.

HaploX Biotechnology, Co., Ltd, Shenzhen, China.

出版信息

Int J Cancer. 2021 Apr 15;148(8):2036-2047. doi: 10.1002/ijc.33460. Epub 2021 Jan 11.

DOI:10.1002/ijc.33460
PMID:33403690
Abstract

Pseudomyxoma peritonei (PMP) is a rare disorder with unique pathological and genetic changes. Although several studies have reported the clinical features and mutational changes of PMP that originates from the appendix, few studies on PMP originating from the ovary have been reported due to its extreme rarity. In order to characterize the somatic mutational landscape and to investigate the prognosis predicting factors of ovary-originating PMP, we examined 830 cases of PMP and identified 16 patients with PMP that originated from the ovary. Whole-exome sequencing (WES) was performed on 12 cases using formalin-fixed, paraffin-embedded (FFPE) tissue samples. We found that 25% (3/12) of the patients carried mutations in cancer driver genes, including TP53, ATM and SETD2, and 16.7% (2/12) of the patients carried mutations in cancer driver genes, including ATRX, EP300, FGFR2, KRAS, NOCR1 and RB1. The MUC16 (58.33%), BSN (41.67%), PCNT (41.67%), PPP2R5A (41.67%), PRSS36 (41.67%), PTPRK (41.67%) and SBF1 (41.67%) genes presented the highest mutational frequencies. The PI3K-Akt signaling pathway, human papillomavirus infection pathway, cell skeleton, cell adhesion, and extracellular matrix and membrane proteins were the major pathways or functions that were affected. Patients were followed up to 174 months (median: 48.26 months). The 5-year OS rate for all patients was 71.2% and the median OS was not reached. PTPRK mutations, presurgical CA199 level, completeness of cytoreduction (CCR) and peritoneal cancer index (PCI) were identified as potential predictive factors for patient survival. In conclusion, the mutational landscape for ovary-originating PMP was revealed and exhibited unique features distinct from appendix-originating PMP. PTPRK, CA199, CCR and PCI may predict patient survival.

摘要

腹膜假性黏液瘤(PMP)是一种罕见疾病,具有独特的病理和遗传改变。虽然有几项研究报告了起源于阑尾的 PMP 的临床特征和突变变化,但由于其极为罕见,因此很少有研究报告起源于卵巢的 PMP。为了描述卵巢起源的 PMP 的体细胞突变景观,并研究预测预后的因素,我们检查了 830 例 PMP 病例,并确定了 16 例起源于卵巢的 PMP 患者。我们对 12 例使用福尔马林固定、石蜡包埋(FFPE)组织样本进行了全外显子组测序(WES)。我们发现,25%(3/12)的患者携带癌症驱动基因的突变,包括 TP53、ATM 和 SETD2,16.7%(2/12)的患者携带癌症驱动基因的突变,包括 ATRX、EP300、FGFR2、KRAS、NOCR1 和 RB1。MUC16(58.33%)、BSN(41.67%)、PCNT(41.67%)、PPP2R5A(41.67%)、PRSS36(41.67%)、PTPRK(41.67%)和 SBF1(41.67%)基因的突变频率最高。PI3K-Akt 信号通路、人乳头瘤病毒感染途径、细胞骨架、细胞黏附和细胞外基质和膜蛋白是受影响的主要途径或功能。患者随访时间为 174 个月(中位数:48.26 个月)。所有患者的 5 年 OS 率为 71.2%,中位 OS 未达到。PTPRK 突变、术前 CA199 水平、肿瘤细胞减灭术(CCR)和腹膜癌指数(PCI)被确定为患者生存的潜在预测因素。总之,揭示了卵巢起源的 PMP 的突变景观,并表现出与阑尾起源的 PMP 不同的独特特征。PTPRK、CA199、CCR 和 PCI 可能预测患者的生存。

相似文献

1
The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.源自卵巢的假性黏液瘤腹膜转移的突变特征和预后指标。
Int J Cancer. 2021 Apr 15;148(8):2036-2047. doi: 10.1002/ijc.33460. Epub 2021 Jan 11.
2
Molecular profiles of high-grade and low-grade pseudomyxoma peritonei.高级别和低级别腹膜假黏液瘤的分子特征
Cancer Med. 2015 Dec;4(12):1809-16. doi: 10.1002/cam4.542. Epub 2015 Oct 16.
3
Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis.腹膜假黏液瘤中 Kras 突变和 p53 过表达:与表型和预后的关系。
J Surg Res. 2013 Mar;180(1):97-103. doi: 10.1016/j.jss.2012.10.053. Epub 2012 Nov 20.
4
Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.阑尾源性腹膜假黏液瘤(PMP):针对一种罕见恶性肿瘤治疗的分子剖析
Am J Clin Oncol. 2018 Aug;41(8):777-783. doi: 10.1097/COC.0000000000000376.
5
Analysis of Mutation and Loss of Heterozygosity by Whole-Exome Sequencing Yields Insights into Pseudomyxoma Peritonei.全外显子组测序分析突变和杂合性丢失为腹膜假黏液瘤提供了新见解。
J Mol Diagn. 2018 Sep;20(5):635-642. doi: 10.1016/j.jmoldx.2018.05.002. Epub 2018 Jun 22.
6
Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei.全外显子组测序鉴定与阑尾黏液性腹膜假黏液瘤预后相关的突变谱和基于突变特征的聚类。
Mol Cancer Res. 2024 Jan 2;22(1):70-81. doi: 10.1158/1541-7786.MCR-22-0801.
7
Histological origin of pseudomyxoma peritonei in Chinese women: clinicopathology and immunohistochemistry.中国人的腹膜假黏液瘤的组织学起源:临床病理和免疫组织化学。
World J Gastroenterol. 2011 Aug 14;17(30):3531-7. doi: 10.3748/wjg.v17.i30.3531.
8
Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations.应用大规模平行测序对阑尾上皮性肿瘤进行分子谱分析以鉴定体细胞突变。
Clin Chem. 2014 Jul;60(7):1004-11. doi: 10.1373/clinchem.2014.225565. Epub 2014 May 12.
9
Pathological prognostic factors of pseudomyxoma peritonei: comprehensive clinicopathological analysis of 155 cases.腹膜假性黏液瘤的病理预后因素:155 例综合临床病理分析。
Hum Pathol. 2020 Mar;97:9-18. doi: 10.1016/j.humpath.2019.12.008. Epub 2020 Jan 9.
10
Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry.使用下一代测序和免疫组织化学分析腹膜假黏液瘤的基因组特征。
Int J Cancer. 2015 Mar 1;136(5):E282-9. doi: 10.1002/ijc.29245. Epub 2014 Oct 13.

引用本文的文献

1
Prognosis conferred by molecular features of appendix-derived Pseudomyxoma Peritonei.阑尾源性腹膜假黏液瘤分子特征所赋予的预后
Transl Oncol. 2025 Mar;53:102279. doi: 10.1016/j.tranon.2025.102279. Epub 2025 Feb 9.
2
Comparison of functional characterization of cancer stem cells in different tumor tissues of pseudomyxoma peritonei.比较腹膜假黏液瘤不同肿瘤组织中癌症干细胞的功能特征。
J Transl Med. 2024 Nov 14;22(1):1022. doi: 10.1186/s12967-024-05730-6.
3
Pseudomyxoma Peritonei Arising From a Mucinous Ovarian Borderline Tumor Treated With Paclitaxel, Cisplatin, and Bevacizumab: A Case Report.
紫杉醇、顺铂和贝伐单抗治疗黏液性卵巢交界性肿瘤所致腹膜假黏液瘤:病例报告
Cureus. 2024 Aug 23;16(8):e67554. doi: 10.7759/cureus.67554. eCollection 2024 Aug.
4
MUC16: clinical targets with great potential.MUC16:极具潜力的临床靶点。
Clin Exp Med. 2024 May 17;24(1):101. doi: 10.1007/s10238-024-01365-5.
5
Ovarian Causes of Pseudomyxoma Peritonei (PMP)-A Literature Review.腹膜假黏液瘤(PMP)的卵巢病因——文献综述
Cancers (Basel). 2024 Apr 9;16(8):1446. doi: 10.3390/cancers16081446.
6
Rapid recurrence of a ruptured mucinous borderline ovarian tumor harboring mutation followed by progression into anaplastic carcinoma with mutation.携带 突变的黏液性交界性卵巢肿瘤破裂后迅速复发,随后进展为携带 突变的间变性癌。
Heliyon. 2022 Oct 3;8(10):e10877. doi: 10.1016/j.heliyon.2022.e10877. eCollection 2022 Oct.
7
Accidental discovery of appendiceal carcinoma during gynecological surgery: A case report.妇科手术中意外发现阑尾癌:一例报告
World J Clin Cases. 2022 Aug 6;10(22):8040-8044. doi: 10.12998/wjcc.v10.i22.8040.